Arcutis Biotherapeutics is a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with unmet medical needs. Co.'s primary product candidate, roflumilast cream, has the potential to provide symptomatic improvement in psoriasis patients similar to the combination of a high potency steroid and calcipotriene, a tolerability profile, the ability to be used chronically, and little to none of the application site reactions associated with various existing topical treatments. Co. is also developing a foam formulation of topical roflumilast for the treatment of scalp psoriasis and seborrheic dermatitis. The ARQT average annual return since 2020 is shown above.
The Average Annual Return on the ARQT average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ARQT average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ARQT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|